Clinical developments over the Christmas period
Trial results in Covid-19 and cancer emerge, but little promise is seen.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Last-ditch rally saves 2019 float tally
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
